Nav: Home

New proposal published in RIO tackles problematic trial detection in

December 17, 2015

Clinical trials are crucial in determining the effectiveness of treatments and directly influence practical and policy decisions. However, their results could be even detrimental to real-life patients if data is fabricated or subject to errors. While it is about 2% of all researchers that admit to having manipulated their data, a new Dutch Fulbright project proposal, published via the innovative Research Ideas & Outcomes (RIO) Journal, suggests new methods to tackle these issues and to apply them to results reported in the database.

Decisions based on bad data, both clinical and policy ones made by medical doctors and governmental institutions, respectively, can pose direct risks on treated patients and the population in general. Such was the case of beta-blockers, for instance, used to be prescribed to cardiac patients in order to decrease perioperative mortality. However, a subsequent meta-analysis detected erroneous data in the related clinical trials. Moreover, it turned out that beta-blockers actually increase the risk of mortality.

The new Dutch Fulbright proposal led by Chris HJ Hartgerink, Tilburg University, Netherlands, and Dr. Stephen L George, Duke University, United States, proposes new additional statistical methods for erroneous data detection to provide an additional quality control filter for clinical trial results reported in the database.

Unfortunately, misleading data is not simply the product of bad practice, but could also result from human error or inadequate data handling. It is not even clear enough how often such mistakes or manipulations occur and have occurred in reality, let alone their prevalence in any science in particular. What is beyond doubt, however, is that additional methods and procedures of detecting bad data are needed in order to minimize the risk of bad decisions being taken when health and wellbeing are at stake.

"Detecting problematic data is a niche field with few experts around the world, despite its importance," further explains Chris HJ Hartgerink. "Systematic application remains absent and this project hopes to push this field into this area. New estimates of how prevalent problematic data are welcome, because we currently rely on self-report measures, which suffer from human bias."

Recently submitted to Fulbright, the 6-month project proposal has now been made open-access by the authors with RIO Journal, an innovative platform publishing all outputs of the research cycle, including: project proposals, data, methods, workflows, software, project reports and research articles.

"A grant proposal is a research output like any other but is only rewarded when it results in funding," says Chris HJ Hartgerink. "We know that many good proposals are rejected and consequently not rewarded. Publishing the grant proposal shows the output, makes it rewardable and can help improve it by post-publication peer review."
Original Source:

Hartgerink CHJ, George SL (2015) Problematic trial detection in Research Ideas and Outcomes 1: e7462. doi: 10.3897/rio.1.e7462

Additional Information:

The Research Ideas and Outcomes (RIO) Journal publishes all outputs of the research cycle, including: project proposals, data, methods, workflows, software, project reports and research articles together on a single collaborative platform offering one of the most transparent, open and public peer-review processes. Its scope encompasses all areas of academic research, including science, technology, the humanities and the social sciences.

Pensoft Publishers

Related Clinical Trials Articles:

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.
Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.
Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.
Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.
When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.
More Clinical Trials News and Clinical Trials Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...